主页 > 医学信息 >
【medical-news】新的辅助化疗药唑来膦酸对乳腺癌
http://www.medicalnewstoday.com/articles/132761.php
SAN ANTONIO - New data suggest that adjuvant treatment with the bisphosphonate zoledronic acid (Zometa) plus chemotherapy may have a direct anti-tumor effect in women with breast cancer who are at high risk of a relapse.
The findings were reported here at the 2008 San Antonio Breast Cancer Symposium (SABCS).
Overall, the addition of zoledronic acid to chemotherapy before surgery produced an additional 33 percent decrease in tumor size, thereby reducing the need for mastectomy.
In addition, the data showed for the first time that zoledronic acid can help shrink primary tumors.
Robert Coleman, MD, with the University of Sheffield (UK), and colleagues elsewhere set out to determine whether the addition of zoledronic acid to chemotherapy influences pathological response to the primary tumor.
For the trial, the investigators used a subgroup of women who were enrolled in the Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE) study, which explored whether treatment with zoledronic acid on top of adjuvant or neoadjuvant chemotherapy would improve disease outcomes in 3,360 women with stage II/III primary breast cancer.
Eligible patients received neoadjuvant chemotherapy according to local practice and were randomized to receive zoledronic acid 4 mg IV three to four times each week for six months in the neoadjuvant period in addition to chemotherapy or no additional treatment.
The primary surrogate endpoint for response was pathologically assessed residual invasive tumor size (RITS, mm) at surgery.
In the trial, 104 patients in the neoadjuvant subset received chemotherapy, and 101 patients received chemotherapy plus zoledronic acid.
Results showed a median RITS of 30 mm in the chemotherapy group and 20.5 in the chemotherapy plus zoledronic acid group. After controlling for variables like estrogen receptor status and treatment duration, results were 42.2 mm in the chemotherapy and 28.2 in the combination group, which amounts to a significant 33% reduction.
The pathological complete response rate was 5.8 percent in the chemotherapy arm versus 10.9 percent in the zoledronic acid group.
Importantly, the need for mastectomy was reduced by 16 percent in the zoledronic acid group.
"Overall, the data add to the evidence of a possible anti-tumor effect for zoledronic acid," Dr. Matthew Winter, MB, a co-author and clinical research fellow at the University of Sheffield, said.
Earlier this year, researchers reported phase III Austrian Breast & Colorectal Cancer Study that zoledronic acid added to endocrine therapy improves survival in premenopausal breast cancer patients.
According to the American Cancer Society, more than 1.3 million women worldwide were newly diagnosed with breast cancer in 2007.
Written by Jill Stein
jillstein03(at)gmail.com
Jill Stein is a Paris-based freelance medical writer.
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 周末玩了两天。明天一定要翻译完毕。 Zoledronic Acid With Neoadjuvant Chemotherapy May Boost Pathological Response In Breast Cancer Patients
新的辅助化疗药唑来膦酸对乳腺癌有效
SAN ANTONIO - New data suggest that adjuvant treatment with the bisphosphonate zoledronic acid (Zometa) plus chemotherapy may have a direct anti-tumor effect in women with breast cancer who are at high risk of a relapse.
圣安东尼奥:新证据表明唑来膦酸（择泰）作为化疗的辅助疗法可能会对遭受乳腺癌复发风险的女人们有直接的抗肿瘤作用。
The findings were reported here at the 2008 San Antonio Breast Cancer Symposium (SABCS).
这项发现发表在2008年的圣安东尼奥乳腺癌座谈会上。
Overall, the addition of zoledronic acid to chemotherapy before surgery produced an additional 33 percent decrease in tumor size, thereby reducing the need for mastectomy.
手术前化疗辅助于唑来膦酸治疗可以使肿瘤大小下降了33%，因此减少了乳房切除术的需求。
In addition, the data showed for the first time that zoledronic acid can help shrink primary tumors.
此外，试验数据首次显示唑来膦酸可以帮助缩小原发性肿瘤。
Robert Coleman, MD, with the University of Sheffield (UK), and colleagues elsewhere set out to determine whether the addition of zoledronic acid to chemotherapy influences pathological response to the primary tumor.
Robert Coleman与谢菲尔德大学的同事们此外还设计实验证明添加唑来膦酸作为化疗的辅助治疗对于原发性肿瘤是否有效。
For the trial, the investigators used a subgroup of women who were enrolled in the Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE) study, which explored whether treatment with zoledronic acid on top of adjuvant or neoadjuvant chemotherapy would improve disease outcomes in 3,360 women with stage II/III primary breast cancer.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-15 17:11
医学,生命科学网